Pfizer Valuation
Is PFE * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PFE * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PFE * (MX$448.17) is trading below our estimate of fair value (MX$1035.17)
Significantly Below Fair Value: PFE * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PFE *?
Other financial metrics that can be useful for relative valuation.
What is PFE *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$148.75b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.6x |
Enterprise Value/EBITDA | 18.4x |
PEG Ratio | 3.1x |
Price to Earnings Ratio vs Peers
How does PFE *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 21.4x | ||
LAB B Genomma Lab Internacional. de | 13.2x | 27.1% | Mex$13.6b |
SAN Sanofi | 20.3x | 13.6% | €109.5b |
AZN AstraZeneca | 36.8x | 16.3% | UK£176.0b |
ROG Roche Holding | 15.4x | 8.2% | CHF179.0b |
PFE * Pfizer | 69.7x | 22.3% | Mex$148.8b |
Price-To-Earnings vs Peers: PFE * is expensive based on its Price-To-Earnings Ratio (69.7x) compared to the peer average (21.4x).
Price to Earnings Ratio vs Industry
How does PFE *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Earnings vs Industry: PFE * is expensive based on its Price-To-Earnings Ratio (69.7x) compared to the Global Pharmaceuticals industry average (24.2x).
Price to Earnings Ratio vs Fair Ratio
What is PFE *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 69.7x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PFE *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$448.17 | Mex$541.81 +20.9% | 15.4% | Mex$771.08 | Mex$445.51 | n/a | 22 |
Apr ’25 | Mex$459.67 | Mex$548.13 +19.2% | 18.6% | Mex$838.07 | Mex$435.79 | n/a | 22 |
Mar ’25 | Mex$452.08 | Mex$556.76 +23.2% | 18.4% | Mex$850.93 | Mex$442.48 | n/a | 23 |
Feb ’25 | Mex$466.00 | Mex$563.93 +21.0% | 19.3% | Mex$854.33 | Mex$444.25 | n/a | 22 |
Jan ’25 | Mex$487.37 | Mex$558.95 +14.7% | 19.9% | Mex$845.62 | Mex$388.98 | n/a | 22 |
Dec ’24 | Mex$496.00 | Mex$694.99 +40.1% | 23.1% | Mex$1,289.78 | Mex$550.30 | n/a | 22 |
Nov ’24 | Mex$550.00 | Mex$728.77 +32.5% | 22.4% | Mex$1,335.92 | Mex$569.99 | n/a | 22 |
Oct ’24 | Mex$579.00 | Mex$760.63 +31.4% | 21.3% | Mex$1,284.46 | Mex$548.04 | n/a | 22 |
Sep ’24 | Mex$612.50 | Mex$744.41 +21.5% | 21.0% | Mex$1,261.28 | Mex$538.14 | n/a | 23 |
Aug ’24 | Mex$603.15 | Mex$770.41 +27.7% | 19.9% | Mex$1,264.60 | Mex$590.15 | n/a | 23 |
Jul ’24 | Mex$629.58 | Mex$792.52 +25.9% | 19.2% | Mex$1,283.40 | Mex$598.92 | n/a | 22 |
Jun ’24 | Mex$667.00 | Mex$819.34 +22.8% | 18.8% | Mex$1,316.51 | Mex$614.37 | n/a | 22 |
May ’24 | Mex$698.00 | Mex$888.42 +27.3% | 16.1% | Mex$1,357.31 | Mex$723.90 | n/a | 22 |
Apr ’24 | Mex$732.99 | Mex$940.36 +28.3% | 16.0% | Mex$1,396.58 | Mex$744.84 | Mex$459.67 | 22 |
Mar ’24 | Mex$729.76 | Mex$944.06 +29.4% | 15.3% | Mex$1,378.92 | Mex$735.42 | Mex$452.08 | 21 |
Feb ’24 | Mex$821.82 | Mex$960.58 +16.9% | 15.1% | Mex$1,396.58 | Mex$744.84 | Mex$466.00 | 21 |
Jan ’24 | Mex$995.00 | Mex$1,070.14 +7.6% | 12.3% | Mex$1,472.93 | Mex$864.12 | Mex$487.37 | 21 |
Dec ’23 | Mex$978.92 | Mex$1,043.99 +6.6% | 12.6% | Mex$1,456.03 | Mex$854.20 | Mex$496.00 | 21 |
Nov ’23 | Mex$945.03 | Mex$1,069.88 +13.2% | 13.7% | Mex$1,495.72 | Mex$877.49 | Mex$550.00 | 19 |
Oct ’23 | Mex$877.27 | Mex$1,110.45 +26.6% | 13.1% | Mex$1,493.81 | Mex$876.37 | Mex$579.00 | 19 |
Sep ’23 | Mex$940.32 | Mex$1,153.49 +22.7% | 12.9% | Mex$1,530.33 | Mex$979.41 | Mex$612.50 | 19 |
Aug ’23 | Mex$1,037.00 | Mex$1,154.99 +11.4% | 12.6% | Mex$1,528.04 | Mex$977.95 | Mex$603.15 | 19 |
Jul ’23 | Mex$1,057.99 | Mex$1,141.92 +7.9% | 13.6% | Mex$1,502.40 | Mex$921.47 | Mex$629.58 | 21 |
Jun ’23 | Mex$1,030.85 | Mex$1,127.13 +9.3% | 13.2% | Mex$1,470.05 | Mex$940.83 | Mex$667.00 | 22 |
May ’23 | Mex$1,007.19 | Mex$1,185.45 +17.7% | 13.7% | Mex$1,533.83 | Mex$968.74 | Mex$698.00 | 21 |
Apr ’23 | Mex$1,017.64 | Mex$1,182.13 +16.2% | 14.5% | Mex$1,542.04 | Mex$933.34 | Mex$732.99 | 21 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.